🇺🇸 FDA
Pipeline program

Etripamil

MSP-2017-1138

Phase 3 small_molecule terminated

Quick answer

Etripamil for Paroxysmal Supraventricular Tachycardia is a Phase 3 program (small_molecule) at Milestone Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Milestone Pharmaceuticals
Indication
Paroxysmal Supraventricular Tachycardia
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials